MicroPort Endovascular MedTech Ltd

MicroPort Endovascular MedTech Ltd

688016 · SHG · Healthcare / Medical Devices

86.34CNY+1.04 (+1.22%)

Price History

Full chart

Market Stats

Previous Close85.30
Open85.63
Day Range85.02 – 88.10
52-Week Range82.36 – 116.00
Volume1.93M
Market Cap10.54B
P/E (TTM)17.92
Forward P/E0.00
EPS4.77
Dividend Yield2.69%
Beta0.05
50-Day Avg89.38
200-Day Avg96.12

About

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Qing Zhu Ph.D.
  • Employees859
  • HeadquartersNo. 1, Lane 3399, Shanghai, China, 201318, China
  • Websitehttps://www.endovastec.com

Leadership

  • Mr. Qing Zhu Ph.D.GM & Director · b. 1981
  • Ms. Chun Fang LiAccounting Supervisor & CFO · b. 1980
  • Mr. Zhenyu YuanDeputy GM, Core Technical Personnel & Employee Representative Director · b. 1977
  • Mr. Lantao GuoDeputy GM & Core Technical Personnel · b. 1966
  • Mr. Ke ChenSenior Director · b. 1980
  • Ms. Dong Mei YanBoard Secretary
  • Ms. Hongjie LuCore Technical Staff · b. 1983
  • Ms. Liwen WangCore Technical Staff · b. 1982

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue125.33M165.13M231.13M333.73M470.25M684.63M896.50M1.19B1.21B1.35B
Growth (%)-+31.76%+39.96%+44.39%+40.91%+45.59%+30.95%+32.43%+1.61%+11.96%
Cost of Revenue29.97M38.13M49.87M72.63M101.72M154.00M224.74M285.93M330.27M390.57M
Gross Profit95.36M127.01M181.26M261.10M368.53M530.63M671.76M901.27M876.06M1.35B
Gross Margin76.09%76.91%78.42%78.24%78.37%77.51%74.93%75.92%72.62%100.00%
Operating Expense50.50M53.09M76.41M96.84M118.60M167.86M256.54M327.42M214.89M696.74M
Operating Income44.85M73.92M104.85M164.27M249.93M362.78M415.21M573.85M661.17M653.89M
Operating Margin35.79%44.76%45.36%49.22%53.15%52.99%46.31%48.34%54.81%48.41%
EBITDA50.28M77.02M111.71M174.26M263.59M379.05M438.88M598.34M688.67M687.82M
EBITDA Margin40.12%46.64%48.33%52.22%56.05%55.37%48.95%50.40%57.09%50.93%
Net Income41.11M63.39M90.65M141.76M214.61M315.86M356.88M492.43M502.10M563.21M
Net Income Margin32.81%38.38%39.22%42.48%45.64%46.14%39.81%41.48%41.62%41.70%
R&D20.08M20.14M29.67M49.64M73.01M102.27M137.54M172.88M93.77M67.79M
R&D as % of Total Revenue16.02%12.19%12.84%14.87%15.52%14.94%15.34%14.56%7.77%5.02%
Interest Expense442.38K58.25K79.06K107.48K114.96K1.93M2.33M2.04M2.03M2.16M
Interest Expense % of Total Revenue0.35%0.04%0.03%0.03%0.02%0.28%0.26%0.17%0.17%0.16%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets188.60M224.26M268.82M1.16B1.38B1.75B2.00B4.25B4.29B4.64B
Total Liabilities65.22M36.24M52.66M89.74M142.09M231.47M252.49M382.63M469.13M-3.98B
Total Equity123.38M188.02M216.16M1.07B1.23B1.49B1.72B3.84B3.79B3.98B
Cash27.71M31.84M49.90M889.21M1.05B1.24B976.89M2.97B2.17B2.00B
Total Debt713.22K943.27K1.32M3.58M18.51M45.81M41.18M35.75M27.97M-
Net Debt-27.00M-30.89M-48.58M-885.62M-1.03B-1.20B-935.71M-2.92B-2.14B-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow30.13M69.36M106.85M143.20M217.44M300.25M333.76M571.22M373.60M573.06M
Investing Cash Flow-31.97M-27.84M-24.79M-11.07M-8.67M-74.57M-439.80M-177.09M-733.14M-
Financing Cash Flow16.71M-37.40M-64.00M707.16M-46.79M-39.85M-159.96M1.60B-534.98M-
Capital Expenditure31.81M28.23M24.90M21.24M26.22M89.58M293.98M190.26M212.65M303.03M
Free Cash Flow-1.67M41.13M81.95M121.97M191.22M210.67M39.78M368.05M160.95M270.03M
Dividends Paid7.36M37.40M64.00M22.50M46.79M64.78M151.15M165.55M450.46M201.83M
FCF to OCF-5.55%59.30%76.69%85.17%87.94%70.17%11.92%64.43%43.08%47.12%
Dividend Paid to FCF-440.02%90.93%78.10%18.45%24.47%30.75%379.94%44.98%279.87%74.75%

Earnings

Report DateAug 27, 2019Oct 27, 2019Feb 27, 2020Apr 26, 2020Aug 27, 2020Oct 28, 2020Feb 26, 2021Apr 19, 2021Aug 24, 2021Oct 28, 2021Feb 24, 2022Apr 29, 2022Aug 25, 2022Oct 28, 2022Feb 27, 2023Apr 27, 2023Jul 28, 2023Oct 27, 2023Feb 23, 2024Apr 26, 2024Aug 26, 2024Oct 29, 2024Feb 27, 2025
EPS Estimate0.00-----0.630.560.560.660.961.021.321.021.471.321.211.081.561.061.241.501.21
EPS Actual0.270.420.410.830.850.580.720.370.400.910.921.151.270.800.781.161.451.021.411.501.771.22-0.45
Surprise------14.29%-33.93%-28.57%37.88%-4.17%12.75%-3.79%-21.57%-46.94%-12.12%19.83%-5.56%-9.62%41.51%42.74%-18.67%-137.19%
TimingAfter-hoursPre-marketPre-marketAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap10.54B
Enterprise Value8.47B
Trailing P/E17.92
Forward P/E0.00
Price / Sales7.37
Price / Book2.50
EPS4.77
Book Value35.23
Revenue (TTM)1.43B
Gross Profit (TTM)1.02B
EBITDA651.25M
Profit Margin39.93%
Operating Margin41.03%
Return on Equity13.48%
Return on Assets7.70%
Shares Outstanding123.26M
Shares Float71.15M
Beta0.05
Dividend Yield2.69%
Dividend Rate2.30
Payout Ratio48.22%

Dividends

20231×
2.30May 18, 2023
20221×
2.10Jul 12, 2022
20211×
0.90Jun 4, 2021
20201×
0.65Jun 22, 2020